Natco and its US-based marketing partner Mylan are fighting Teva Pharmaceutical Industries over a generic version of the latters blockbuster drug Copaxone used to treat multiple sclerosis. In February, Teva launched a 40 mg three-times-a-week version of the drug, replacing the once-daily 20 mg formulation, by the end of May.
Mylan was expecting approval for the generic version in May but with the courts agreeing to hear Tevas appeal on the validity of the Copaxone patent, it can only do so at risk.
Lupin received a jolt when the US-based Warner Chilcott launched the oral contraceptive pill Lo Loestrin 24 Fe, with comparatively lower levels of estrogen to replace the earlier version that was set to lose patent protection in July 2014. This product now goes off-patent only in February 2029, according to a class-action lawsuit launched against Chilcott.
In January 2014, the US district court of New Jersey upheld Chilcotts patent of the new Loestrin. While Lupin had agreed not to launch a generic before the patent expiry, it is unlikely to gain market share since patients may not switch to a generic version.
In another instance, Chilcott had entered into a settlement with Lupin for Asacol, a treatment for a type of inflammatory bowel disease. However, in March 2013, the US company replaced Asacol with Delzicol and discontinued the former drug.
Warner Chilcott has successfully managed to switch about 100% Rx to new variants in case of two of its brands i.e. Asacol and Loestrin Fe. This has been a negative surprise for Lupin, which planned to launch Loestrin Fe in July 2014 and had a settlement to launch Asacol authorised generic, IDFC Institutional Equities director (equity research) Nitin Agarwal observed. Warner Chilcott was acquired by Actavis in 2013.
Both companies had taken a leaf out of Abbott Laboratories book. Abbott launched Tricor, generically known as fenofibrate in 1998, almost five years after US Food and Drug Administration gave its approval in 1993.
In November 2000, Novopharm USA which was later acquired by Teva filed an ANDA for approval of a generic version of Tricor.
The filing automatically triggered a patent infringement lawsuit by Abbott, which in turn imposed a 30-month stay on approval of any generic versions of the drug by the USFDA.
Eighteen months into the stay, Abbott launched Tricor-2, a branded reformulation of Tricor in the dosages of 54 mg and 160 mg. The company submitted studies showing that the new dosages had the same pharmacologic properties as the original 67 mg, 134 mg and 200 mg versions, based on bioequivalence studies and zero clinical trials.
The strategies adopted by the majors is paying off. Tevas new Copaxone formulation reached 2,019 prescriptions in the week ending March 21, accounting for 21% of total Copaxone volumes, according to Bloomberg. The company is targeting a 45% patient switch and with growth averaging 403 bps in the last four weeks, it has already surpassed the 300-bps targeted weekly rise needed to achieve the switch, as per the data.